Amgen and Kyowa Kirin Co., Ltd. unveiled preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults as well as adolescents with moderate to severe atopic dermatitis (AD). The ASCEND study watches participants who finished earlier rocatinlimab trials for a longer time. About 2,200 t... https://www.coherentmarketinsights.com/news/amgen-and-kyowa-kirin-share-early-results-from-their-phase-3-study-1491